Vertex Pharmaceuticals (NASDAQ:VRTX) Rating Reiterated by Cantor Fitzgerald
Cantor Fitzgerald reissued their overweight rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) in a research note published on Tuesday morning, Benzinga reports. Cantor Fitzgerald currently has a $380.00 price objective on the pharmaceutical company’s stock. A number of other brokerages also recently issued reports on VRTX. HC Wainwright raised their price target […]
More Stories
Aaron Wealth Advisors LLC Lowers Holdings in Nomura Holdings, Inc. (NYSE:NMR)
Aaron Wealth Advisors LLC lowered its position in shares of Nomura Holdings, Inc. (NYSE:NMR – Free Report) by 7.4% in...
Cadence Design Systems, Inc. (NASDAQ:CDNS) Shares Bought by Stonegate Investment Group LLC
Stonegate Investment Group LLC boosted its stake in shares of Cadence Design Systems, Inc. (NASDAQ:CDNS – Free Report) by 1.3%...
Trust Point Inc. Decreases Stake in Franklin Electric Co., Inc. (NASDAQ:FELE)
Trust Point Inc. reduced its stake in Franklin Electric Co., Inc. (NASDAQ:FELE – Free Report) by 8.6% in the 3rd...
Onto Innovation Inc. (NYSE:ONTO) Shares Sold by Trust Point Inc.
Trust Point Inc. lessened its holdings in shares of Onto Innovation Inc. (NYSE:ONTO – Free Report) by 21.2% during the...
Stonegate Investment Group LLC Cuts Stock Holdings in S&P Global Inc. (NYSE:SPGI)
Stonegate Investment Group LLC cut its stake in S&P Global Inc. (NYSE:SPGI – Free Report) by 8.3% in the third...
Vert Asset Management LLC Acquires 588 Shares of American Tower Co. (NYSE:AMT)
Vert Asset Management LLC increased its stake in American Tower Co. (NYSE:AMT – Free Report) by 0.6% in the 3rd...